ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry Q9WMX2


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name POLG_HCVCO
Primary accession number Q9WMX2
Secondary accession numbers None
Integrated into Swiss-Prot on July 5, 2005
Sequence was last modified on January 23, 2007 (Sequence version 3)
Annotations were last modified on    July 22, 2008 (Entry version 69)
Name and origin of the protein
Protein name Genome polyprotein
Synonyms None
Contains Core protein p21
     (Capsid protein C)
     (p21)
Core protein p19
Envelope glycoprotein E1
     (gp32)
     (gp35)
Envelope glycoprotein E2
     (NS1)
     (gp68)
     (gp70)
p7
Protease NS2-3
     (p23)
     (EC 3.4.22.-)
Serine protease/NTPase/helicase NS3
     (EC 3.4.21.98)
     (EC 3.6.1.15)
     (EC 3.6.1.-)
     (Hepacivirin)
     (NS3P)
     (p70)
Non-structural protein 4A
     (NS4A)
     (p8)
Non-structural protein 4B
     (NS4B)
     (p27)
Non-structural protein 5A
     (NS5A)
     (p56)
RNA-directed RNA polymerase
     (EC 2.7.7.48)
     (NS5B)
     (p68)
Gene name None
From
Hepatitis C virus genotype 1b (isolate Con1) (HCV) [TaxID: 333284] 
Taxonomy Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae; Hepacivirus.
Virus host Homo sapiens (Human) [TaxID: 9606]
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [GENOMIC RNA].
DOI=10.1126/science.285.5424.110; PubMed=10390360 [NCBI, ExPASy, EBI, Israel, Japan]
Lohmann V., Koerner F., Koch J.O., Herian U., Theilmann L., Bartenschlager R.;
"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.";
Science 285:110-113(1999).
[2]
FUNCTION OF NS3 AND NS4A.
DOI=10.1126/science.1082604; PubMed=12702807 [NCBI, ExPASy, EBI, Israel, Japan]
Foy E., Li K., Wang C., Sumpter R. Jr., Ikeda M., Lemon S.M., Gale M. Jr.;
"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.";
Science 300:1145-1148(2003).
[3]
FUNCTION OF NS5A.
DOI=10.1128/JVI.78.23.13306-13314.2004; PubMed=15542681 [NCBI, ExPASy, EBI, Israel, Japan]
Neddermann P., Quintavalle M., Di Pietro C., Clementi A., Cerretani M., Altamura S., Bartholomew L., De Francesco R.;
"Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture.";
J. Virol. 78:13306-13314(2004).
[4]
MUTAGENESIS OF SER-2158; SER-2173; SER-2179; SER-2194; SER-2197; SER-2200; SER-2201; SER-2202; SER-2204; SER-2207; SER-2210; SER-2246; SER-2255 AND SER-2269.
DOI=10.1128/JVI.79.5.3187-3194.2005; PubMed=15709040 [NCBI, ExPASy, EBI, Israel, Japan]
Appel N., Pietschmann T., Bartenschlager R.;
"Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain.";
J. Virol. 79:3187-3194(2005).
[5]
INTERACTION WITH HUMAN TBK1.
DOI=10.1002/hep.20666; PubMed=15841462 [NCBI, ExPASy, EBI, Israel, Japan]
Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N., Kawabe T., Omata M.;
"Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses.";
Hepatology 41:1004-1012(2005).
[6]
PHOSPHORYLATION BY HOST CSNK1A1.
STRAIN=Isolate HCV-AT;
DOI=10.1128/JVI.01465-06; PubMed=16943283 [NCBI, ExPASy, EBI, Israel, Japan]
Quintavalle M., Sambucini S., Di Pietro C., De Francesco R., Neddermann P.;
"The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation.";
J. Virol. 80:11305-11312(2006).
[7]
REVIEW.
DOI=10.1046/j.1365-2893.2000.00201.x; PubMed=10718937 [NCBI, ExPASy, EBI, Israel, Japan]
McLauchlan J.;
"Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes.";
J. Viral Hepat. 7:2-14(2000).
[8]
REVIEW, AND SUBCELLULAR LOCATION.
DOI=10.1002/hep.20032; PubMed=14752815 [NCBI, ExPASy, EBI, Israel, Japan]
Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
"Structural biology of hepatitis C virus.";
Hepatology 39:5-19(2004).
[9]
X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 2008-2170, AND DISULFIDE BOND.
DOI=10.1038/nature03580; PubMed=15902263 [NCBI, ExPASy, EBI, Israel, Japan]
Tellinghuisen T.L., Marcotrigiano J., Rice C.M.;
"Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase.";
Nature 435:374-379(2005).
Comments
  • FUNCTION: Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).
  • FUNCTION: E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).
  • FUNCTION: P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).
  • FUNCTION: Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).
  • FUNCTION: NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves the host antiviral protein MAVS (By similarity). NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state.
  • FUNCTION: NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).
  • FUNCTION: NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).
  • FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an essential role in the virus replication (By similarity).
  • CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
  • CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1).
  • CATALYTIC ACTIVITY: NTP + H2O = NDP + phosphate.
  • COFACTOR: Binds 1 zinc ion per NS3 protease domain (By similarity).
  • COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By similarity).
  • ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on zinc ions and completely inhibited by EDTA. Serine protease NS3 is also activated by zinc ions (By similarity).
  • SUBUNIT: Core protein is a homomultimer that binds the C-terminal part of E1 and interacts with numerous cellular proteins. Interaction with human STAT1 SH2 domain seems to result in decreased STAT1 phosphorylation, leading to decreased IFN-stimulated gene transcription. In addition to blocking the formation of phosphorylated STAT1, the core protein also promotes ubiquitin-mediated proteasome-dependent degradation of STAT1. Interacts with, and constitutively activates human STAT3. Associates with human LTBR and TNFRSF1A receptors and possibly induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK, C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins. Interacts with human CREB3 nuclear transcription protein, triggering cell transformation. May interact with human p53. Also binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1 and E2 glycoproteins form a heterodimer that binds to human LDLR, CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR. p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing a pair of composite active sites at the dimerization interface. NS2 seems to interact with all other non-structural (NS) proteins. NS4A interacts with NS3 serine protease and stabilizes its folding. NS3-NS4A complex is essential for the activation of the latter and allows membrane anchorage of NS3. NS3 interacts with human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form homodimers and seem to interact with all other non-structural (NS) proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2, BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B is a homooligomer and interacts with human VAPB (By similarity).
  • INTERACTION:
    P06241:FYN (xeno); NbExp=2; IntAct=EBI-710918, EBI-515315;
    P62993:GRB2 (xeno); NbExp=1; IntAct=EBI-710918, EBI-401755;
    P08631:HCK (xeno); NbExp=1; IntAct=EBI-710918, EBI-346340;
    P06239:LCK (xeno); NbExp=1; IntAct=EBI-710918, EBI-1348;
    P07948:LYN (xeno); NbExp=2; IntAct=EBI-710918, EBI-79452;
  • SUBCELLULAR LOCATION: Core protein p21: Endoplasmic reticulum membrane; Single-pass membrane protein (By similarity). Mitochondrion membrane; Single-pass type I membrane protein (By similarity). Lipid droplet membrane; Single-pass membrane protein (By similarity). Note=The C-terminal transmembrane domain of core protein p21 contains an ER signal leading the nascent polyprotein to the ER membrane. Only a minor proportion of core protein is present in the nucleus and an unknown proportion is secreted.
  • SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity). Cytoplasm (By similarity). Nucleus (By similarity). Secreted (By similarity).
  • SUBCELLULAR LOCATION: Envelope glycoprotein E1: Endoplasmic reticulum membrane; Single-pass type I membrane protein (By similarity). Note=The C-terminal transmembrane domain acts as a signal sequence and forms a hairpin structure before cleavage by host signal peptidase. After cleavage, the membrane sequence is retained at the C-terminus of the protein, serving as ER membrane anchor. A reorientation of the second hydrophobic stretch occurs after cleavage producing a single reoriented transmembrane domain. These events explain the final topology of the protein. ER retention of E1 is leaky and, in overexpression conditions, only a small fraction reaches the plasma membrane.
  • SUBCELLULAR LOCATION: Envelope glycoprotein E2: Endoplasmic reticulum membrane; Single-pass type I membrane protein (By similarity). Note=The C-terminal transmembrane domain acts as a signal sequence and forms a hairpin structure before cleavage by host signal peptidase. After cleavage, the membrane sequence is retained at the C-terminus of the protein, serving as ER membrane anchor. A reorientation of the second hydrophobic stretch occurs after cleavage producing a single reoriented transmembrane domain. These events explain the final topology of the protein. ER retention of E2 is leaky and, in overexpression conditions, only a small fraction reaches the plasma membrane.
  • SUBCELLULAR LOCATION: p7: Endoplasmic reticulum membrane; Multi-pass membrane protein (By similarity). Cell membrane (By similarity). Note=The C-terminus of p7 membrane domain acts as a signal sequence. After cleavage by host signal peptidase, the membrane sequence is retained at the C-terminus of the protein, serving as ER membrane anchor. Only a fraction localizes to the plasma membrane.
  • SUBCELLULAR LOCATION: Protease NS2-3: Endoplasmic reticulum membrane; Multi-pass membrane protein (Potential).
  • SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Endoplasmic reticulum membrane; Peripheral membrane protein (By similarity). Note=NS3 is associated to the ER membrane through its binding to NS4A.
  • SUBCELLULAR LOCATION: Non-structural protein 4A: Endoplasmic reticulum membrane; Single-pass type I membrane protein (Potential). Note=Membrane insertion occurs after processing by the NS3 protease.
  • SUBCELLULAR LOCATION: Non-structural protein 4B: Endoplasmic reticulum membrane; Multi-pass membrane protein (By similarity).
  • SUBCELLULAR LOCATION: Non-structural protein 5A: Endoplasmic reticulum membrane; Peripheral membrane protein (By similarity). Cytoplasm, perinuclear region (By similarity). Mitochondrion (By similarity). Note=Membrane insertion occurs after processing by the NS3 protease.
  • SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Endoplasmic reticulum membrane; Single-pass type I membrane protein (Potential). Note=Membrane insertion occurs after processing by the NS3 protease.
  • DOMAIN: The transmembrane regions of envelope E1 and E2 glycoproteins are involved in heterodimer formation, ER localization, and assembly of these proteins. Envelope E2 glycoprotein contain two highly variable regions called hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two segments involved in CD81-binding. HVR1 is implicated in the SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be involved in sensitivity and/or resistance to IFN-alpha therapy (By similarity).
  • DOMAIN: The N-terminus of NS5A acts as membrane anchor. The central part of NS5A contains a variable region called interferon sensitivity determining region (ISDR) and seems to be intrinsically disordered and interacts with NS5B and host PKR. The C-terminus of NS5A contains a variable region called variable region 3 (V3). ISDR and V3 may be involved in sensitivity and/or resistance to IFN-alpha therapy (By similarity).
  • DOMAIN: The SH3-binding domain of NS5A is involved in the interaction with human Bin1, GRB2 and Src-family kinases (By similarity).
  • DOMAIN: The N-terminal one-third of serine protease NS3 contains the protease activity. This region contains a zinc atom that does not belong to the active site, but may play a structural rather than a catalytic role. This region is essential for the activity of protease NS2-3, maybe by contributing to the folding of the latter. The helicase activity is located in the C-terminus of NS3 (By similarity).
  • PTM: Specific enzymatic cleavages in vivo yield mature proteins. The structural proteins, core, E1, E2 and p7 are produced by proteolytic processing by host signal peptidases. The core protein is synthesized as a 21 kDa precursor which is retained in the ER membrane through the hydrophobic signal peptide. Cleavage by the signal peptidase releases the 19 kDa mature core protein. The other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are cleaved by the viral proteases (By similarity).
  • PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated (By similarity).
  • PTM: Core protein is phosphorylated by host PKC and PKA (By similarity).
  • PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an hyperphosphorylated form of p56. p56 and p58 coexist in the cell in roughly equivalent amounts. Hyperphosphorylation is dependent on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1, MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for NS5A phosphorylation (By similarity).
  • PTM: NS4B is palmitoylated. This modification may play a role in its polymerization or in protein-protein interactions (By similarity).
  • PTM: The N-terminus of a fraction of NS4B molecules seems to be relocated post-translationally from the cytoplasm to the ER lumen, with a 5th transmembrane segment. The C-terminus of NS2 may be lumenal with a fourth transmembrane segment (By similarity).
  • PTM: Core protein is ubiquitinated; mediated by UBE3A and leading to core protein subsequent proteasomal degradation (By similarity).
  • MISCELLANEOUS: Cell culture adaptation of the virus leads to mutations in NS5A, reducing its inhibitory effect on replication (By similarity).
  • MISCELLANEOUS: Core protein exerts viral interference on hepatitis B virus when HCV and HBV coinfect the same cell, by suppressing HBV gene expression, RNA encapsidation and budding (By similarity).
  • SIMILARITY: Belongs to the hepaciviruses polyprotein family.
  • SIMILARITY: Contains 1 helicase ATP-binding domain.
  • SIMILARITY: Contains 1 peptidase C18 domain [view classification].
  • SIMILARITY: Contains 1 peptidase S29 domain [view classification].
  • SIMILARITY: Contains 1 RdRp catalytic domain.
  • CAUTION: The core gene probably also codes for alternative reading frame proteins (ARFPs). Many functions depicted for the core protein might belong to the ARFPs.
  • WEB RESOURCE: Name=euHCVdb; Note=The European HCV database; URL="http://euhcvdb.ibcp.fr";.
  • WEB RESOURCE: Name=HCV databases; URL="http://hcv.lanl.gov/content/hcv-db/";.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
AJ238799; CAB46677.1; -; Genomic_RNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
PIR A61196; A61196.
PQ0246; PQ0246.
PS0329; PS0329.
3D structure databases
PDB
1ZH1; X-ray; 2.50 A; A/B=2008-2170.[ExPASy / RCSB / EBI]
PDBsum 1ZH1; -.
ModBase Q9WMX2.
Protein-protein interaction databases
IntAct Q9WMX2; -.
Organism-specific databases
euHCVdb AJ238799; -.
Ontologies
GO
GO:0005515; Molecular function: protein binding (inferred from physical interaction from IntAct).
QuickGo view.
Family and domain databases
InterPro IPR014001; DEAD-like_N.
IPR001650; DNA/RNA_helicase_C.
IPR002522; HCV_capsid.
IPR002521; HCV_core.
IPR002519; HCV_env.
IPR002531; HCV_NS1.
IPR000745; HCV_NS4a.
IPR001490; HCV_NS4b.
IPR002868; HCV_NS5a.
IPR013193; HCV_NS5a_1b.
IPR014021; Helicase_SF1/SF2_ATP-bd.
IPR002518; Pept_C18_HCV_NS2.
IPR004109; Peptidase_S29.
IPR002166; RNA_pol_HCV.
IPR007094; RNA_pol_PSvir.
IPR013192; Znf_HCV_NS5a.
Graphical view of domain structure.
Pfam PF01543; HCV_capsid; 1.
PF01542; HCV_core; 1.
PF01539; HCV_env; 1.
PF01560; HCV_NS1; 1.
PF01538; HCV_NS2; 1.
PF01006; HCV_NS4a; 1.
PF01001; HCV_NS4b; 1.
PF01506; HCV_NS5a; 1.
PF08300; HCV_NS5a_1a; 1.
PF08301; HCV_NS5a_1b; 1.
PF00271; Helicase_C; 1.
PF02907; Peptidase_S29; 1.
PF00998; RdRP_3; 1.
Pfam graphical view of domain structure.
SMART SM00487; DEXDc; 1.
SMART graphical view of domain structure.
PROSITE PS51192; HELICASE_ATP_BIND_1; 1.
PS51194; HELICASE_CTER; FALSE_NEG.
PS50507; RDRP_SSRNA_POS; 1.
PROSITE graphical view of domain structure (profiles).
BLOCKS Q9WMX2.
Other
ProtoNet Q9WMX2.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein; Cell membrane; Complete proteome; Cytoplasm; Endoplasmic reticulum; Envelope protein; Fusion protein; Glycoprotein; Helicase; Host-virus interaction; Hydrolase; Interferon antiviral system evasion; Lipid droplet; Lipoprotein; Membrane; Metal-binding; Mitochondrion; Multifunctional enzyme; Nucleotide-binding; Nucleotidyltransferase; Nucleus; Oncogene; Palmitate; Phosphoprotein; Protease; Ribonucleoprotein; RNA replication; RNA-binding; RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding; Thiol protease; Transcription; Transcription regulation; Transferase; Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom    To Length Description FTId
INIT_MET   1      1        Removed; by host (By similarity). 
CHAIN   2    191  190     Core protein p21 (Potential). PRO_0000037541
CHAIN   2    177  176     Core protein p19 (By similarity). PRO_0000037542
PROPEP   178    191  14     ER anchor for the core protein, removed in mature form by host signal peptidase (By similarity). PRO_0000037543
CHAIN   192    383  192     Envelope glycoprotein E1 (Potential). PRO_0000037544
CHAIN   384    746  363     Envelope glycoprotein E2 (Potential). PRO_0000037545
CHAIN   747    809  63     p7 (By similarity). PRO_0000037546
CHAIN   810   1026  217     Protease NS2-3 (Potential). PRO_0000037547
CHAIN   1027   1657  631     Serine protease/NTPase/helicase NS3 (Potential). PRO_0000037548
CHAIN   1658   1711  54     Non-structural protein 4A (Potential). PRO_0000037549
CHAIN   1712   1972  261     Non-structural protein 4B (Potential). PRO_0000037550
CHAIN   1973   2419  447     Non-structural protein 5A (Potential). PRO_0000037551
CHAIN   2420   3010  591     RNA-directed RNA polymerase (Potential). PRO_0000037552
TOPO_DOM   2    168  167     Cytoplasmic (Potential). 
TRANSMEM   169    189  21     Potential. 
TOPO_DOM   190    358  169     Lumenal (Potential). 
TRANSMEM   359    379  21     Potential. 
TOPO_DOM   380    725  346     Lumenal (Potential). 
TRANSMEM   726    746  21     Potential. 
TOPO_DOM   747    757  11     Lumenal (Potential). 
TRANSMEM   758    778  21     Potential. 
TOPO_DOM   779    782  4     Cytoplasmic (Potential). 
TRANSMEM   783    803  21     Potential. 
TOPO_DOM   804    813  10     Lumenal (Potential). 
TRANSMEM   814    834  21     Potential. 
TOPO_DOM   835    881  47     Cytoplasmic (Potential). 
TRANSMEM   882    902  21     Potential. 
TOPO_DOM   903    928  26     Lumenal (Potential). 
TRANSMEM   929    949  21     Potential. 
TOPO_DOM   950   1657  708     Cytoplasmic (Potential). 
TRANSMEM   1658   1678  21     Potential. 
TOPO_DOM   1679   1805  127     Cytoplasmic (Potential). 
TRANSMEM   1806   1826  21     Potential. 
TOPO_DOM   1827   1828  2     Lumenal (Potential). 
TRANSMEM   1829   1849  21     Potential. 
TOPO_DOM   1850   1850  1     Cytoplasmic (Potential). 
TRANSMEM   1851   1871  21     Potential. 
TOPO_DOM   1872   1881  10     Lumenal (Potential). 
TRANSMEM   1882   1902  21     Potential. 
TOPO_DOM   1903   1972  70     Cytoplasmic (Potential). 
TOPO_DOM   1973   2002  30     In membrane (By similarity). 
TOPO_DOM   2003   2989  987     Cytoplasmic (Potential). 
TRANSMEM   2990   3010  21     By similarity. 
DOMAIN   1217   1369  153     Helicase ATP-binding. 
DOMAIN   2633   2751  119     RdRp catalytic. 
NP_BIND   1230   1237  8     ATP (Potential). 
REGION   2     59  58     Interaction with DDX3X (By similarity). 
REGION   2     23  22     Interaction with STAT1 (By similarity). 
REGION   122    173  52     Interaction with APOA2 (By similarity).